Department of Defense Increases Development Contract With Cleveland BioLabs for CBLB502

Cleveland BioLabs, Inc. CBLI today announced that it received a $1,531,034 increase (including option) in the development portion of the Company's existing contract, awarded on September 16, 2010, from the United States Department of Defense Chemical Biological and Medical Systems Medical Identification and Treatment Systems to fund additional development activities for CBLB502, a medical radiation countermeasure. Michelle Ross, DVM, M.S, Ph.D., Senior Vice President of Public Health and Government Services for Cleveland BioLabs, commented, "We are very pleased to have additional support from the DoD to conduct further development activities to bring CBLB502 towards licensure in direct support of the warfighter. There is currently no FDA approved countermeasure for exposure to total body irradiation and the development activities sponsored by this contract support our collaborative efforts to advance CBLB502 towards a Biologic License Application to fulfill this unmet need."